Acceleron Reports Oral Plenary Presentation for ACE-083 in Late-Breaking Trial

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, announced that a late breaking abstract describing results from the ACE-083 Phase 1 clinical trial has been selected for an oral plenary presentation in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia, and Muscle Wasting. The conference will take place in Paris, France, December 4-6, 2015. ACE-083 has been designed to increase muscle mass and strength selectively in the muscles into which the drug is administered. Acceleron is developing ACE-083 for diseases such as facioscapulohumeral and certain other forms of muscular dystrophy in which improved muscle strength in a specific set of muscles may provide a clinical benefit. Oral Presentation Date: Saturday, December 5 Title: A Phase 1 Dose Escalation Study of ACE-083 in Healthy Volunteers: Preliminary Results for a Locally Acting Muscle Therapeutic (Abstract #1-72) Session: 55. Clinical science track: Late breaking clinical trials & trial updates Time: 4:30 - 6:30 PM CET Location: Novotel Paris Tour Eiffel, Hall A Poster Presentation Date: Sunday, December 6 Title: A Phase 1 Dose Escalation Study of ACE-083 in Healthy Volunteers: Preliminary Results for a Locally Acting Muscle Therapeutic (Abstract #1-72) Session: 16. Muscle wasting, sarcopenia, myopenia VI Time: 9:35 - 10:25 AM CET Location: Novotel Paris Tour Eiffel, Poster Area The clinical presentation and poster will be available on Acceleron's website (www.acceleronpharma.com) under the "Publications" tab when presented at the conference.